ALK gets German approval extended: “An important part of our strategy for the future”

Allergy business ALK expects to strengthen its position in the German market after the company received the green light from the country’s authorities to reduce the necessary number of inejctions per treatment round by more than half.

ALK believe they can become stronger within the large German market with the extended approval. Photo: ALK / PR/peter

Log in to read our articles

Welcome to MedWatch. A part of our content is exclusive and reserved for our users.

Try us for 14 days

Try a trial subscription for access to our quality journalism

Related articles